Login to Your Account



Gilead Gets Letairis Approval, Potential Best In Class For PAH

By Trista Morrison


Tuesday, June 19, 2007
While Encysive Pharmaceuticals Inc. received a third approvable letter for Thelin (sitaxsentan sodium) on Friday, Gilead Sciences Inc. got approval for Letairis (ambrisentan), a competing endothelin A receptor antagonist for pulmonary arterial hypertension (PAH). (See Encysive story this issue).(BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription